G9016 – Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only]
HCPCS Level II code · G codes: Procedures / Professional Services (Temporary)
HCPCS codeG9016
- Long description
- Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only]
- Short description
- Demo-smoking cessation coun
- Pricing indicator
00Not separately priced by Part B (bundled, not covered or Part A only)- Medicare coverage
MNon-covered by Medicare- BETOS category
Y2Other - Non-Medicare fee schedule- Added
- January 1, 2001
- Last change
- January 1, 2001 – No change
Frequently asked questions
What is HCPCS code G9016?
G9016 is a HCPCS Level II code for smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only].
Does Medicare cover G9016?
The HCPCS file lists coverage code M: Non-covered by Medicare. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby G codes
- G9007 – Coordinated care fee, scheduled team conference
- G9008 – Coordinated care fee, physician coordinated care oversight services
- G9009 – Coordinated care fee, risk adjusted maintenance, level 3
- G9010 – Coordinated care fee, risk adjusted maintenance, level 4
- G9011 – Coordinated care fee, risk adjusted maintenance, level 5
- G9012 – Other specified case management service not elsewhere classified
- G9013 – Esrd demo basic bundle level i
- G9014 – Esrd demo expanded bundle including venous access and related services
- G9017 – Amantadine hydrochloride, oral, per 100 mg (for use in a medicare-approved demonstration project)
- G9018 – Zanamivir, inhalation powder, administered through inhaler, per 10 mg (for use in a medicare-approved demonstration project)
- G9019 – Oseltamivir phosphate, oral, per 75 mg (for use in a medicare-approved demonstration project)
- G9020 – Rimantadine hydrochloride, oral, per 100 mg (for use in a medicare-approved demonstration project)
- G9033 – Amantadine hydrochloride, oral brand, per 100 mg (for use in a medicare-approved demonstration project)
- G9034 – Zanamivir, inhalation powder, administered through inhaler, brand, per 10 mg (for use in a medicare-approved demonstration project)
- G9035 – Oseltamivir phosphate, oral, brand, per 75 mg (for use in a medicare-approved demonstration project)
- G9036 – Rimantadine hydrochloride, oral, brand, per 100 mg (for use in a medicare-approved demonstration project)
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.